4D Molecular Therapeutics Partners with Roche on Gene Therapy Vectors

One Bench at a Time

4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel gene delivery vectors for use in gene therapy products. Financial details were not disclosed.

“We are thrilled to enter into this collaboration with Roche, a global leader in research-focused healthcare,” said Dr. David Kirn, co-founder and CEO of 4DMT. “We believe that great synergies can be achieved by combining our AAV gene therapy platform discovery with Roche’s expertise in novel biologics. Together we can potentially develop transformative new gene therapies. As the fourth collaboration to be announced by 4D over the last year, we are realizing our vision of creating a robust product pipeline with our partners.”

Read the press release at Business Wire

Upcoming Event

  • San Carlos Open House

    Come to meet MBC BioLabs residents, tour our new space in San Carlos, and hear about our exciting plans for the future. There will be posters from our companies, a live band, and an opportunity to chat with our partners and staff. RSVP In just 4 years, we have helped 116 entrepreneurial teams create fast, focused and frugal biotech companies that have gone on to raise $2.4 billion and counting. With this new facility, we can empower more entrepreneurs with the space and resources they need to tackle world changing science. Come join us in celebrating our newest MBC Biolabs campus and welcome our residents and partners!


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter